

**CLAIMS AMENDMENTS**

Please amend claim 1 as shown below. All other claims are unchanged.

1. (currently amended) A preparation for topically delivering and localizing therapeutic agents, comprising:

a vasoconstrictor for retarding vascular dispersion of a therapeutic agent; and

a penetration enhancer for facilitating penetration of said vasoconstrictor and said therapeutic agent through a patient's skin; wherein:

said therapeutic agent is separate and distinct from said vasoconstrictor itself.

2. (original) The preparation of claim 1, said vasoconstrictor comprising *phenylephrine*.

3. (original) The preparation of claim 2, wherein:

a clinical concentration of said *phenylephrine* is at least approximately 0.125%; and

said clinical concentration of said *phenylephrine* is at most approximately 1.0%.

4. (original) The preparation of claim 3, wherein said clinical concentration of said *phenylephrine* is approximately 0.5%.

5. (original) The preparation of claim 1, said vasoconstrictor comprising a vasoconstrictor selected from the vasoconstrictor group consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and *oxymetazoline*.

6. (original) The preparation of claim 1, said penetration

2 enhancer comprising *dimethylsulfoxide*.

1 7. (original) The preparation of claim 6, wherein a clinical  
2 concentration of said *dimethylsulfoxide* is at most approximately  
3 10%.

1 8. (original) The preparation of claim 7, wherein said  
2 clinical concentration of said *dimethylsulfoxide* is approximately  
3 10%.

1 9. (original) The preparation of claim 1, said penetration  
2 enhancer comprising *lecithin*.

1 10. (original) The preparation of claim 9, said penetration  
2 enhancer further comprising *ethoxy diglycol*.

1 11. (original) The preparation of claim 9, wherein:  
2 a clinical concentration of said *lecithin* is at least  
3 approximately 2%; and  
4 said clinical concentration of said *lecithin* is at most  
5 approximately 50%.

1 12. (original) The preparation of claim 11, wherein:  
2 said clinical concentration of said *lecithin* is  
3 approximately 10% to 12%.

1 13. (original) The preparation of claim 1:  
2 said vasoconstrictor comprising *phenylephrine*; and  
3 said penetration enhancer comprising *dimethylsulfoxide*.

1 14. (original) The preparation of claim 13, wherein:  
2 a clinical concentration of said *phenylephrine* is at least  
3 approximately 0.125%;  
4 said clinical concentration of said *phenylephrine* is at most  
5 approximately 1.0%; and

6 a clinical concentration of said *dimethylsulfoxide* is at  
7 most approximately 10%.

1 15. (original) The preparation of claim 14, wherein:

2 said clinical concentration of said *phenylephrine* is  
3 approximately 0.5%; and

4 said clinical concentration of said *dimethylsulfoxide* is  
5 approximately 10%.

1 16. (original) The preparation of claim 13, wherein:

2 a ratio of a clinical concentration of said  
3 *dimethylsulfoxide* to a clinical concentration of said  
4 *phenylephrine* is at most approximately 40 to 1.

1 17. (original) The preparation of claim 1:

2 said vasoconstrictor comprising *phenylephrine*; and  
3 said penetration enhancer comprising *lecithin*.

1 18. (original) The preparation of claim 17, said penetration  
2 enhancer further comprising *ethoxy diglycol*.

1 19. (original) The preparation of claim 17, wherein:

2 a clinical concentration of said *phenylephrine* is at least  
3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most  
5 approximately 1.0%; and

6 a clinical concentration of said *lecithin* is at most  
7 approximately 50%.

1 20. (original) The preparation of claim 19, wherein:

2 said clinical concentration of said *phenylephrine* is  
3 approximately 0.5%; and

4 said clinical concentration of said *lecithin* is

5 approximately 10% to 12%.

1 21. (original) The preparation of claim 17, wherein:

2 a ratio of a clinical concentration of said *lecithin* to a  
3 clinical concentration of said *phenylephrine* is at most  
4 approximately 200 to 1.

1 22. (original) The preparation of claim 1, further comprising:

2 said therapeutic agent.

1 23. (original) The preparation of claim 22, particularly for  
2 relieving pain, comprising:

3 said therapeutic agent comprising a therapeutic pain-  
4 relieving agent;

5 said penetration enhancer for facilitating penetration of  
6 said therapeutic pain-relieving agent and said vasoconstrictor  
7 through the patient's skin; and

8 said vasoconstrictor for retarding vascular dispersion of  
9 said therapeutic agent.

1 24. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a local anesthetic.

1 25. (original) The preparation of claim 24, said local  
2 anesthetic comprising *bupivacaine*.

1 26. (original) The preparation of claim 25, wherein:

2 a clinical concentration of said *bupivacaine* is at least  
3 approximately 2%; and

4 said clinical concentration of said *bupivacaine* is at most  
5 approximately 10%.

1 27. (original) The preparation of claim 26, wherein said

2 clinical concentration of said *bupivacaine* is approximately 5%.

1 28. (original) The preparation of claim 24, said local  
 2 anesthetic comprising a local anesthetic selected from the local  
 3 anesthetic group consisting of: *mepivacaine*, *levobupivacaine*,  
 4 *ropivacaine*, *chloroprocaine*, *procaine*, *lidocaine*, *etidocaine*,  
 5 *benzocaine*, *tetracaine*, and *prilocaine*.

1 29. (original) The preparation of claim 23, said therapeutic  
 2 pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory  
 4 agent.

1 30. (original) The preparation of claim 29, said quick-onset,  
 2 short-acting non-steroidal anti-inflammatory agent comprising  
 3 *ketoprofen*.

1 31. (original) The preparation of claim 30, wherein:

2 a clinical concentration of said *ketoprofen* is at least  
 3 approximately 5%; and

4 said clinical concentration of said *ketoprofen* is at most  
 5 approximately 20%.

1 32. (original) The preparation of claim 31, wherein said  
 2 clinical concentration of said *ketoprofen* is approximately 10%.

1 33. (original) The preparation of claim 29, said quick-onset,  
 2 short-acting non-steroidal anti-inflammatory agent comprising a  
 3 quick-onset, short-acting non-steroidal anti-inflammatory agent  
 4 selected from the quick-onset, short-acting non-steroidal anti-  
 5 inflammatory agent group consisting of: *diclofenac*, *diflunisal*,  
 6 *etodolac*, *fenoprofen*, *flurbiprofen*, *ibuprofen*, *indomethacin*, and  
 7 *tolmetin*.

1 34. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a long-acting non-steroidal anti-inflammatory agent.

1 35. (original) The preparation of claim 34, said long-acting  
2 non-steroidal anti-inflammatory agent comprising *piroxicam*.

1 36. (original) The preparation of claim 35, wherein:

2 a clinical concentration of said *piroxicam* is at least  
3 approximately 0.5%; and

4 said clinical concentration of said *piroxicam* is at most  
5 approximately 4%.

1 37. (original) The preparation of claim 36, wherein said  
2 clinical concentration of said *piroxicam* is approximately 1.0%.

1 38. (original) The preparation of claim 34, said long-acting  
2 non-steroidal anti-inflammatory agent comprising a long-acting  
3 non-steroidal anti-inflammatory agent selected from the long-  
4 acting non-steroidal anti-inflammatory agent group consisting of:  
5 *celecoxib, meloxicam, nabumetone, naproxen, oxaprozin, rofecoxib,*  
6 *sulindac, and valdecoxib.*

1 39. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a local anesthetic; and

4 a quick-onset, short-acting non-steroidal anti-inflammatory  
5 agent.

1 40. (original) The preparation of claim 39:

2 said local anesthetic comprising *bupivacaine*; and

3 said quick-onset, short-acting non-steroidal anti-  
4 inflammatory agent comprising *ketoprofen*.

1 41. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a local anesthetic; and

4 a long-acting non-steroidal anti-inflammatory agent.

1 42. (original) The preparation of claim 41:

2 said local anesthetic comprising *bupivacaine*; and

3 said long-acting non-steroidal anti-inflammatory agent  
4 comprising *piroxicam*.

1 43. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a quick-onset, short-acting non-steroidal anti-inflammatory  
4 agent; and

5 a long-acting non-steroidal anti-inflammatory agent.

1 44. (original) The preparation of claim 43:

2 said quick-onset, short-acting non-steroidal anti-  
3 inflammatory agent comprising *ketoprofen*; and

4 said long-acting non-steroidal anti-inflammatory agent  
5 comprising *piroxicam*.

1 45. (original) The preparation of claim 23, said therapeutic  
2 pain-relieving agent comprising:

3 a local anesthetic;

4 a quick-onset, short-acting non-steroidal anti-inflammatory  
5 agent; and

6 a long-acting non-steroidal anti-inflammatory agent.

1 46. (original) The preparation of claim 45:

2 said local anesthetic comprising *bupivacaine*;

3 said quick-onset, short-acting non-steroidal anti-

4 inflammatory agent comprising *ketoprofen*; and

5       said long-acting non-steroidal anti-inflammatory agent  
6 comprising *piroxicam*.

1 47. (original) The preparation of claim 46, wherein:

2       a clinical concentration of said *bupivacaine* is at least  
3 approximately 2%;

4       said clinical concentration of said *bupivacaine* is at most  
5 approximately 10%;

6       a clinical concentration of said *ketoprofen* is at least  
7 approximately 5%;

8       said clinical concentration of said *ketoprofen* is at most  
9 approximately 20%;

10       a clinical concentration of said *piroxicam* is at least  
11 approximately 0.5%; and

12       said clinical concentration of said *piroxicam* is at most  
13 approximately 4%.

1 48. (original) The preparation of claim 47, wherein:

2       said clinical concentration of said *bupivacaine* is  
3 approximately 5%;

4       said clinical concentration of said *ketoprofen* is  
5 approximately 10%; and

6       said clinical concentration of said *piroxicam* is  
7 approximately 1.0%

1 49. (original) The preparation of claim 22, particularly for  
2 treating a viral disease, comprising:

3       said therapeutic agent comprising an antiviral agent;

4       said penetration enhancer for facilitating penetration of



5 said antiviral agent and said vasoconstrictor through the  
6 patient's skin; and

7 said vasoconstrictor for retarding vascular dispersion of  
8 said antiviral agent.

1 50. (original) The preparation of claim 49, said antiviral  
2 agent comprising 2-deoxy-d-glucose.

1 51. (original) The preparation of claim 50, wherein:

2 a clinical concentration of said 2-deoxy-d-glucose is at  
3 least approximately 0.1%; and

4 said clinical concentration of said 2-deoxy-d-glucose is at  
5 most approximately 0.4%.

1 52. (original) The preparation of claim 51, wherein:

2 said clinical concentration of said 2-deoxy-d-glucose is  
3 approximately 0.2%.

1 53. (original) The preparation of claim 49, said antiviral  
2 agent comprising an antiviral agent selected from the antiviral  
3 agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and  
4 *docosanol*.

1 54. (original) The preparation of claim 23, particularly for  
2 relieving pain from a viral disease and treating the viral  
3 disease, comprising:

4 said therapeutic agent further comprising an antiviral  
5 agent;

6 said penetration enhancer for further facilitating  
7 penetration of said antiviral agent through the patient's skin;  
8 and

9 said vasoconstrictor for further retarding vascular

10 dispersion of said antiviral agent.

1 55. (original) The preparation of claim 54, said antiviral  
2 agent comprising *2-deoxy-d-glucose*.

1 56. (original) The preparation of claim 55, wherein:  
2 a clinical concentration of said *2-deoxy-d-glucose* is at  
3 least approximately 0.1%; and  
4 said clinical concentration of said *2-deoxy-d-glucose* is at  
5 most approximately 0.4%.

1 57. (original) The preparation of claim 56, wherein:  
2 said clinical concentration of said *2-deoxy-d-glucose* is  
3 approximately 0.2%.

1 58. (original) The preparation of claim 54, said antiviral  
2 agent comprising an antiviral agent selected from the antiviral  
3 agent group consisting of: *podofilox*, *acyclovir*, *penciclovir*, and  
4 *docosanol*.

1 59. (original) The preparation of claim 45:  
2 said vasoconstrictor comprising *phenylephrine*;  
3 said penetration enhancer comprising a penetration enhancing  
4 agent selected from the penetration-enhancing agent group  
5 consisting of *dimethylsulfoxide* and *lecithin*;  
6 said local anesthetic comprising *bupivacaine*;  
7 said quick-onset, short-acting non-steroidal anti-  
8 inflammatory agent comprising *ketoprofen*; and  
9 said long-acting non-steroidal anti-inflammatory agent  
10 comprising *piroxicam*.

1 60. (original) The preparation of claim 59, wherein:  
2 a clinical concentration of said *phenylephrine* is at least

3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most  
5 approximately 1.0%;

6 a clinical concentration of said *dimethylsulfoxide* is at  
7 most approximately 10%;

8 a clinical concentration of said *lecithin* is at most  
9 approximately 50%;

10 a clinical concentration of said *bupivacaine* is at least  
11 approximately 2%;

12 said clinical concentration of said *bupivacaine* is at most  
13 approximately 10%;

14 a clinical concentration of said *ketoprofen* is at least  
15 approximately 5%;

16 said clinical concentration of said *ketoprofen* is at most  
17 approximately 20%;

18 a clinical concentration of said *piroxicam* is at least  
19 approximately 0.5%; and

20 said clinical concentration of said *piroxicam* is at most  
21 approximately 4%.

1 61. (original) The preparation of claim 60, wherein:

2 said clinical concentration of said *phenylephrine* is  
3 approximately 0.5%;

4 said clinical concentration of said *bupivacaine* is  
5 approximately 5%;

6 said clinical concentration of said *ketoprofen* is  
7 approximately 10%; and

8 said clinical concentration of said *piroxicam* is

9 approximately 1.0%.

1 62. (original) The preparation of claim 45, additionally for  
2 treating a viral disease, said therapeutic agent further  
3 comprising:

4 an antiviral agent.

1 63. (original) The preparation of claim 62:

2 said vasoconstrictor comprising *phenylephrine*;

3 said penetration enhancer comprising a penetration enhancing  
4 agent selected from the penetration-enhancing agent group  
5 consisting of *dimethylsulfoxide* and *lecithin*;

6 said local anesthetic comprising *bupivacaine*;

7 said quick-onset, short-acting non-steroidal anti-  
8 inflammatory agent comprising *ketoprofen*;

9 said long-acting non-steroidal anti-inflammatory agent  
10 comprising *piroxicam*; and

11 said antiviral agent comprising *2-deoxy-d-glucose*.

1 64. (original) The preparation of claim 63, wherein:

2 a clinical concentration of said *phenylephrine* is at least  
3 approximately 0.125%;

4 said clinical concentration of said *phenylephrine* is at most  
5 approximately 1.0%;

6 a clinical concentration of said *dimethylsulfoxide* is at  
7 most approximately 10%;

8 a clinical concentration of said *lecithin* is at most  
9 approximately 50%;

10 a clinical concentration of said *bupivacaine* is at least  
11 approximately 2%;

12        said clinical concentration of said *bupivacaine* is at most  
13 approximately 10%;

14        a clinical concentration of said *ketoprofen* is at least  
15 approximately 5%;

16        said clinical concentration of said *ketoprofen* is at most  
17 approximately 20%;

18        a clinical concentration of said *piroxicam* is at least  
19 approximately 0.5%;

20        said clinical concentration of said *piroxicam* is at most  
21 approximately 4%;

22        a clinical concentration of said *2-deoxy-d-glucose* is at  
23 least approximately 0.1%; and

24        said clinical concentration of said *2-deoxy-d-glucose* is at  
25 most approximately 0.4%.

1    65. (original) The preparation of claim 64, wherein:

2        said clinical concentration of said *phenylephrine* is  
3 approximately 0.5%;

4        said clinical concentration of said *bupivacaine* is  
5 approximately 5%;

6        said clinical concentration of said *ketoprofen* is  
7 approximately 10%;

8        said clinical concentration of said *piroxicam* is  
9 approximately 1.0%; and

10       said clinical concentration of said *2-deoxy-d-glucose* is  
11 approximately 0.2%.

1    66. (original) A method of topically delivering and localizing  
2 therapeutic agents, comprising the steps of:

3        using a vasoconstrictor for retarding vascular dispersion of  
 4        a therapeutic agent; in combination with  
 5        using a penetration enhancer for facilitating penetration of  
 6        said vasoconstrictor and said therapeutic agent through a  
 7        patient's skin.

1        67. (original) The method of claim 66 , said step of using said  
 2        vasoconstrictor further comprising the step of using  
 3        *phenylephrine*.

1        68. (original) The method of claim 67, further comprising the  
 2        steps of:

3        using a clinical concentration of said *phenylephrine*, of at  
 4        least approximately 0.125%; and

5        using said clinical concentration of said *phenylephrine*, of  
 6        at most approximately 1.0%.

1        69. (original) The method of claim 68, further comprising the  
 2        step of using said clinical concentration of said *phenylephrine*,  
 3        of approximately 0.5%.

1        70. (original) The method of claim 66 , said step of using said  
 2        vasoconstrictor further comprising the step of using a  
 3        vasoconstrictor selected from the vasoconstrictor group  
 4        consisting of: *ephedrine sulfate*, *epinephrine*, *naphazoline*, and  
 5        *oxymetazoline*.

1        71. (original) The method of claim 66, said step of using said  
 2        penetration enhancer further comprising the step of using  
 3        *dimethylsulfoxide*.

1        72. (original) The method of claim 71, further comprising the  
 2        step of using a clinical concentration of said *dimethylsulfoxide*,

3 of at most approximately 10%.

1 73. (original) The method of claim 72, further comprising the  
2 step of using said clinical concentration of said  
3 *dimethylsulfoxide*, of approximately 10%.

1 74. (original) The method of claim 66, said step of using said  
2 penetration enhancer further comprising the step of using  
3 comprising *lecithin*.

1 75. (original) The method of claim 74, said step of using said  
2 penetration enhancer further comprising the step of using *ethoxy*  
3 *diglycol*.

1 76. (original) The method of claim 74, further comprising the  
2 steps of:  
3 using a clinical concentration of said *lecithin*, of at least  
4 approximately 2%; and  
5 using said clinical concentration of said *lecithin*, of at  
6 most approximately 50%.

1 77. (original) The method of claim 76, further comprising the  
2 step of:  
3 using said clinical concentration of said *lecithin*, of  
4 approximately 10% to 12%.

1 78. (original) The method of claim 66:  
2 said step of using said vasoconstrictor further comprising  
3 the step of using *phenylephrine*; and  
4 said step of using said penetration enhancer further  
5 comprising the step of using *dimethylsulfoxide*.

1 79. (original) The method of claim 78, further comprising the  
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at  
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of  
6 at most approximately 1.0%; and

7 using a clinical concentration of said *dimethylsulfoxide*, of  
8 at most approximately 10%.

1 80. (original) The method of claim 79, further comprising the  
2 steps of:

3 using said clinical concentration of said *phenylephrine*, of  
4 approximately 0.5%; and

5 using said clinical concentration of said *dimethylsulfoxide*,  
6 of approximately 10%.

1 81. (original) The method of claim 78, further comprising the  
2 step of:

3 using a ratio of a clinical concentration of said  
4 *dimethylsulfoxide* to a clinical concentration of said  
5 *phenylephrine*, of at most approximately 40 to 1.

1 82. (original) The method of claim 66:

2 said step of using said vasoconstrictor further comprising  
3 the step of using *phenylephrine*; and

4 said step of using said penetration enhancer further  
5 comprising the step of using *lecithin*.

1 83. (original) The method of claim 82, said step of using said  
2 penetration enhancer further comprising the step of using *ethoxy*  
3 *diglycol*.

1 84. (original) The method of claim 82, further comprising the  
2 steps of:



using a clinical concentration of said *phenylephrine*, of at least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of at most approximately 1.0%; and

using a clinical concentration of said *lecithin*, of at most approximately 50%.

85. (original) The method of claim 84, further comprising the steps of:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%; and

using said clinical concentration of said *lecithin*, of approximately 10% to 12%.

86. (original) The method of claim 82, further comprising the step of:

using a ratio of a clinical concentration of said *lecithin* to a clinical concentration of said *phenylephrine*, of at most approximately 200 to 1.

87. (original) The method of claim 66, further comprising the step of:

using said therapeutic agent in combination with using said vasoconstrictor and using said penetration enhancer.

88. (original) The method of claim 87, particularly for relieving pain:

said step of using said therapeutic agent further comprising the step of using a therapeutic pain-relieving agent; further comprising the steps of:

using said penetration enhancer for facilitating penetration

7 of said therapeutic pain-relieving agent and said vasoconstrictor  
8 through the patient's skin; and

9 using said vasoconstrictor for retarding vascular dispersion  
10 of said therapeutic agent.

1 89. (original) The method of claim 88, said step of using said  
2 therapeutic pain-relieving agent further comprising the step of  
3 using a local anesthetic.

1 90. (original) The method of claim 89, said step of using said  
2 local anesthetic further comprising the step of using  
3 *bupivacaine*.

1 91. (original) The method of claim 90, further comprising the  
2 steps of:

3 using a clinical concentration of said *bupivacaine*, of at  
4 least approximately 2%; and

5 using said clinical concentration of said *bupivacaine*, of at  
6 most approximately 10%.

1 92. (original) The method of claim 91, further comprising the  
2 step of using said clinical concentration of said *bupivacaine*, of  
3 approximately 5%.

1 93. (original) The method of claim 89, said step of using said  
2 local anesthetic further comprising the step of using a local  
3 anesthetic selected from the local anesthetic group consisting  
4 of: *mepivacaine*, *levobupivacaine*, *ropivacaine*, *chloroprocaine*,  
5 *procaine*, *lidocaine*, *etidocaine*, *benzocaine*, *tetracaine*, and  
6 *prilocaine*.

1 94. (original) The method of claim 88, said step of using said  
2 therapeutic pain-relieving agent further comprising the step of

3 using a quick-onset, short-acting non-steroidal anti-inflammatory  
4 agent.

1 95. (original) The method of claim 94, said step of using said  
2 quick-onset, short-acting non-steroidal anti-inflammatory agent  
3 further comprising the step of using *ketoprofen*.

1 96. (original) The method of claim 95, further comprising the  
2 step of:

3 using a clinical concentration of said *ketoprofen*, of at  
4 least approximately 5%; and

5 said clinical concentration of said *ketoprofen*, of at most  
6 approximately 20%.

1 97. (original) The method of claim 96, further comprising the  
2 step of using said clinical concentration of said *ketoprofen*, of  
3 approximately 10%.

1 98. (original) The method of claim 94, said step of using said  
2 quick-onset, short-acting non-steroidal anti-inflammatory agent  
3 further comprising the step of using a quick-onset, short-acting  
4 non-steroidal anti-inflammatory agent selected from the quick-  
5 onset, short-acting non-steroidal anti-inflammatory agent group  
6 consisting of: *diclofenac*, *diflunisal*, *etodolac*, *fenoprofen*,  
7 *flurbiprofen*, *ibuprofen*, *indomethacin*, and *tolmetin*.

1 99. (original) The method of claim 88, said step of using said  
2 therapeutic pain-relieving agent further comprising the step of  
3 using a long-acting non-steroidal anti-inflammatory agent.

1 100. (original) The method of claim 99, said step of using said  
2 long-acting non-steroidal anti-inflammatory agent further  
3 comprising the step of using *piroxicam*.

1 101. (original) The method of claim 100, further comprising the  
2 steps of:

3 using a clinical concentration of said *piroxicam*, of at  
4 least approximately 0.5%; and

5 using said clinical concentration of said *piroxicam*, of at  
6 most approximately 4%.

1 102. (original) The method of claim 101, further comprising the  
2 step of using said clinical concentration of said *piroxicam*, of  
3 approximately 1.0%.

1 103. (original) The method of claim 99, said step of using said  
2 long-acting non-steroidal anti-inflammatory agent further  
3 comprising the step of using a long-acting non-steroidal anti-  
4 inflammatory agent selected from the long-acting non-steroidal  
5 anti-inflammatory agent group consisting of: *celecoxib*,  
6 *meloxicam*, *nabumetone*, *naproxen*, *oxaprozin*, *rofecoxib*, *sulindac*,  
7 and *valdecoxib*.

1 104. (original) The method of claim 88, said step of using said  
2 therapeutic pain-relieving agent further comprising the steps of:  
3 using a local anesthetic; and  
4 using a quick-onset, short-acting non-steroidal anti-  
5 inflammatory agent.

1 105. (original) The method of claim 104:  
2 said step of using said local anesthetic further comprising  
3 the step of using *bupivacaine*; and  
4 said step of using said quick-onset, short-acting non-  
5 steroidal anti-inflammatory agent further comprising the step of  
6 using *ketoprofen*.

1 106. (original) The method of claim 88, said step of using said  
 2 therapeutic pain-relieving agent further comprising the steps  
 3 of::

4 using a local anesthetic; and  
 5 using a long-acting non-steroidal anti-inflammatory agent.

1 107. (original) The method of claim 106:  
 2 said step of using said local anesthetic further comprising  
 3 the step of using *bupivacaine*; and

4 said step of using said long-acting non-steroidal anti-  
 5 inflammatory agent further comprising the step of using  
 6 *piroxicam*.

1 108. (original) The method of claim 88, said step of using said  
 2 therapeutic pain-relieving agent further comprising the steps  
 3 of::

4 using a quick-onset, short-acting non-steroidal anti-  
 5 inflammatory agent; and  
 6 using a long-acting non-steroidal anti-inflammatory agent.

1 109. (original) The method of claim 108:  
 2 said step of using said quick-onset, short-acting non-  
 3 steroidal anti-inflammatory agent further comprising the step of  
 4 using *ketoprofen*; and

5 said step of using said long-acting non-steroidal anti-  
 6 inflammatory agent further comprising the step of using  
 7 *piroxicam*.

1 110. (original) The method of claim 88, said step of using said  
 2 therapeutic pain-relieving agent further comprising the steps of:  
 3 using a local anesthetic;

using a quick-onset, short-acting non-steroidal anti-inflammatory agent; and

using a long-acting non-steroidal anti-inflammatory agent.

111. (original) The method of claim 110:

said step of using said local anesthetic further comprising the step of using *bupivacaine*;

said step of using said quick-onset, short-acting non-steroidal anti-inflammatory agent further comprising the step of using *ketoprofen*; and

said step of using said long-acting non-steroidal anti-inflammatory agent further comprising the step of using *piroxicam*.

112. (original) The method of claim 111, further comprising the steps of:

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at most approximately 4%.

113. (original) The method of claim 112, further comprising the

2 steps of:

3 using said clinical concentration of said *bupivacaine*, of  
4 approximately 5%;

5 using said clinical concentration of said *ketoprofen*, of  
6 approximately 10%; and

7 using said clinical concentration of said *piroxicam*, of  
8 approximately 1.0%.

1 114. (original) The method of claim 87, particularly for  
2 treating a viral disease:

3 said step of using said therapeutic agent further comprising  
4 the step of using an antiviral agent; further comprising the  
5 steps of:

6 using said penetration enhancer for facilitating penetration  
7 of said antiviral agent and said vasoconstrictor through the  
8 patient's skin; and

9 using said vasoconstrictor for retarding vascular dispersion  
10 of said antiviral agent.

1 115. (original) The method of claim 114, said step of using said  
2 antiviral agent further comprising the step of using *2-deoxy-d-*  
3 *glucose*.

1 116. (original) The method of claim 115, further comprising the  
2 steps of:

3 using a clinical concentration of said *2-deoxy-d-glucose*, of  
4 at least approximately 0.1%; and

5 using said clinical concentration of said *2-deoxy-d-glucose*,  
6 of at most approximately 0.4%.

1 117. (original) The method of claim 116, further comprising the

2 step of:

3 using said clinical concentration of said *2-deoxy-d-glucose*,  
4 of approximately 0.2%.

1 118. (original) The method of claim 114, said step of using said  
2 antiviral agent further comprising the step of using an antiviral  
3 agent selected from the antiviral agent group consisting of:  
4 *podofilox, acyclovir, penciclovir, and docosanol.*

1 119. (original) The method of claim 88, particularly for  
2 relieving pain from a viral disease and treating the viral  
3 disease:

4 said step of using said therapeutic agent further comprising  
5 the step of using an antiviral agent; further comprising the  
6 steps of:

7 using said penetration enhancer for further facilitating  
8 penetration of said antiviral agent through the patient's skin;  
9 and

10 using said vasoconstrictor for further retarding vascular  
11 dispersion of said antiviral agent.

1 120. (original) The method of claim 119, said step of using said  
2 antiviral agent further comprising the step of using *2-deoxy-d-*  
3 *glucose.*

1 121. (original) The method of claim 120, further comprising the  
2 steps of:

3 using a clinical concentration of said *2-deoxy-d-glucose*, of  
4 at least approximately 0.1%; and

5 using said clinical concentration of said *2-deoxy-d-glucose*,  
6 of at most approximately 0.4%.



1 122. (original) The method of claim 121, further comprising the  
2 step of:

3 using said clinical concentration of said *2-deoxy-d-glucose*,  
4 of approximately 0.2%.

1 123. (original) The method of claim 119, said step of using  
2 said antiviral agent further comprising the step of using an  
3 antiviral agent selected from the antiviral agent group  
4 consisting of: *podofilox*, *acyclovir*, *penciclovir*, and *docosanol*.

1 124. (original) The method of claim 110:

2 said step of using said vasoconstrictor further comprising  
3 the step of using *phenylephrine*;

4 said step of using said penetration enhancer further  
5 comprising the step of using a penetration enhancing agent  
6 selected from the penetration-enhancing agent group consisting of  
7 *dimethylsulfoxide* and *lecithin*;

8 said step of using said local anesthetic further comprising  
9 the step of using *bupivacaine*;

10 said step of using said quick-onset, short-acting non-  
11 steroidal anti-inflammatory agent further comprising the step of  
12 using *ketoprofen*; and

13 said step of using said long-acting non-steroidal anti-  
14 inflammatory agent further comprising the step of using  
15 *piroxicam*.

1 125. (original) The method of claim 124, further comprising the  
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at  
4 least approximately 0.125%;

using said clinical concentration of said *phenylephrine*, of  
at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of  
at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most  
approximately 50%;

using a clinical concentration of said *bupivacaine*, of at  
least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at  
most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at  
least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at  
most approximately 20%;

using a clinical concentration of said *piroxicam*, of at  
least approximately 0.5%; and

using said clinical concentration of said *piroxicam*, of at  
most approximately 4%.

126. (original) The method of claim 125, further comprising the  
steps of:

using said clinical concentration of said *phenylephrine*, of  
approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of  
approximately 5%;

using said clinical concentration of said *ketoprofen*, of  
approximately 10%; and

using said clinical concentration of said *piroxicam*, of

10 approximately 1.0%.

1 127. (original) The method of claim 110, additionally for  
2 treating a viral disease, said step of using said therapeutic  
3 agent further comprising the step of using an antiviral agent.

1 128. (original) The method of claim 127:

2 said step of using said vasoconstrictor further comprising  
3 the step of using *phenylephrine*;

4 said step of using said penetration enhancer further  
5 comprising the step of using a penetration enhancing agent  
6 selected from the penetration-enhancing agent group consisting of  
7 *dimethylsulfoxide* and *lecithin*;

8 said step of using said local anesthetic further comprising  
9 the step of using *bupivacaine*;

10 said step of using said quick-onset, short-acting non-  
11 steroidal anti-inflammatory agent further comprising the step of  
12 using *ketoprofen*;

13 said step of using said long-acting non-steroidal anti-  
14 inflammatory agent further comprising the step of using  
15 *piroxicam*; and

16 said step of using said antiviral agent further comprising  
17 the step of using *2-deoxy-d-glucose*.

1 129. (original) The method of claim 128, further comprising the  
2 steps of:

3 using a clinical concentration of said *phenylephrine*, of at  
4 least approximately 0.125%;

5 using said clinical concentration of said *phenylephrine*, of  
6 at most approximately 1.0%;

using a clinical concentration of said *dimethylsulfoxide*, of at most approximately 10%;

using a clinical concentration of said *lecithin*, of at most approximately 50%;

using a clinical concentration of said *bupivacaine*, of at least approximately 2%;

using said clinical concentration of said *bupivacaine*, of at most approximately 10%;

using a clinical concentration of said *ketoprofen*, of at least approximately 5%;

using said clinical concentration of said *ketoprofen*, of at most approximately 20%;

using a clinical concentration of said *piroxicam*, of at least approximately 0.5%;

using said clinical concentration of said *piroxicam*, of at most approximately 4%;

using a clinical concentration of said *2-deoxy-d-glucose*, of at least approximately 0.1%; and

using said clinical concentration of said *2-deoxy-d-glucose*, of at most approximately 0.4%.

130. (original) The method of claim 129, further comprising the steps of:

using said clinical concentration of said *phenylephrine*, of approximately 0.5%;

using said clinical concentration of said *bupivacaine*, of approximately 5%;

using said clinical concentration of said *ketoprofen*, of

8 approximately 10%;  
 9 using said clinical concentration of said *piroxicam*, of  
 10 approximately 1.0%; and  
 11 using said clinical concentration of said *2-deoxy-d-glucose*,  
 12 of approximately 0.2%.

1 131. (original) The method of claim 66, further comprising the  
 2 step of:

3 applying said vasoconstrictor and said penetration enhancer  
 4 to the patient's skin.

1 132. (original) The method of claim 78, further comprising the  
 2 step of:

3 applying said *phenylephrine* and said *dimethylsulfoxide* to  
 4 the patient's skin.

1 133. (original) The method of claim 82, further comprising the  
 2 step of:

3 applying said *phenylephrine* and said *lecithin* to the  
 4 patient's skin.

1 134. (original) The method of claim 87, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 and said therapeutic agent to the patient's skin.

1 135. (original) The method of claim 88, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 and said therapeutic pain-relieving agent to the patient's skin.

1 136. (original) The method of claim 89, further comprising the  
 2 step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said local anesthetic to the patient's skin.

1       137. (original)   The method of claim 90, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said *bupivacaine* to the patient's skin.

1       138. (original)   The method of claim 94, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said quick-onset, short-acting non-steroidal anti-  
5       inflammatory agent to the patient's skin.

1       139. (original)   The method of claim 95, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said *ketoprofen* to the patient's skin.

1       140. (original)   The method of claim 99, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said long-acting non-steroidal anti-inflammatory agent to the  
5       patient's skin.

1       141. (original)   The method of claim 100, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,  
4       and said *piroxicam* to the patient's skin.

1       142. (original)   The method of claim 110, further comprising the  
2       step of:

3       applying said vasoconstrictor, said penetration enhancer,

4 said local anesthetic, said quick-onset, short-acting non-  
 5 steroidal anti-inflammatory agent, and said long-acting non-  
 6 steroidal anti-inflammatory agent to the patient's skin.

1 143. (original) The method of claim 111, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 said *bupivacaine*, said *ketoprofen*, and said *piroxicam* to the  
 5 patient's skin.

1 144. (original) The method of claim 114, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 and said antiviral agent to the patient's skin.

1 145. (original) The method of claim 115, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 and said *2-deoxy-d-glucose* to the patient's skin.

1 146. (original) The method of claim 119, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 therapeutic pain-relieving agent, and said antiviral agent to the  
 5 patient's skin.

1 147. (original) The method of claim 120, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 therapeutic pain-relieving agent, and said *2-deoxy-d-glucose* to  
 5 the patient's skin.

1 148. (original) The method of claim 124, further comprising the

2 step of:

3 applying said *phenylephrine*, said penetration enhancing  
 4 agent selected from the penetration-enhancing agent group  
 5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,  
 6 said *ketoprofen*, and said *piroxicam* to the patient's skin.

1 149. (original) The method of claim 127, further comprising the  
 2 step of:

3 applying said vasoconstrictor, said penetration enhancer,  
 4 said local anesthetic, said quick-onset, short-acting non-  
 5 steroidal anti-inflammatory agent, said long-acting non-steroidal  
 6 anti-inflammatory agent, and said antiviral agent to the  
 7 patient's skin.

1 150. (original) The method of claim 128, further comprising the  
 2 step of:

3 applying said *phenylephrine*, said penetration enhancing  
 4 agent selected from the penetration-enhancing agent group  
 5 consisting of *dimethylsulfoxide* and *lecithin*, said *bupivacaine*,  
 6 said *ketoprofen*, said *piroxicam*;, and said *2-deoxy-d-glucose* to  
 7 the patient's skin.